ABCA1 Knockout HAP1 Cell Line

The choice depends on whether you are studying ABCA1 (ATP-binding cassette transporter A1)'s role as the principal cholesterol efflux transporter or modeling Tangier disease and cardiovascular biology. The Knockout line is the standard tool for asking whether ABCA1 is required for these processes — ABCA1 is an ABC full-transporter that mediates the efflux of cellular cholesterol and phospholipids to lipid-poor apolipoprotein A-I (apoA-I), the rate-limiting first step of reverse cholesterol transport and HDL biogenesis; ABCA1 is critical for cellular cholesterol homeostasis. Overexpression is useful for studying ABCA1 gain-of-function effects. For lipid metabolism and cardiovascular research, the EDITGENE ABCA1 Knockout in HAP1 is uniquely valuable — ABCA1 biallelic loss-of-function causes ⭐⭐ Tangier disease (severe HDL deficiency, cholesterol ester accumulation in tissues, enlarged orange tonsils, premature atherosclerosis); heterozygous ABCA1 mutations cause familial hypoalphalipoproteinemia. Rescue with wild-type or patient-derived ABCA1 mutations enables disease modeling. The knockout is valuable for studying reverse cholesterol transport, HDL biogenesis, macrophage cholesterol efflux (atherosclerosis), and emerging ABCA1-modulating cardiovascular therapeutics (LXR agonists upregulate ABCA1). HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

Primary applications: • Cholesterol efflux: apoA-I-mediated cholesterol and phospholipid efflux analysis in ABCA1-null cells — abolished given ABCA1's rate-limiting role. • HDL biogenesis: in heterologous HDL-relevant contexts, nascent HDL particle formation analysis. • Tangier disease modeling: rescue with patient-derived ABCA1 mutations for Tangier disease/familial hypoalphalipoproteinemia modeling. • Macrophage cholesterol efflux: in heterologous foam-cell-relevant contexts, atherosclerosis-relevant cholesterol efflux studies. • LXR agonist pharmacology: LXR agonist (upregulate ABCA1) mechanism studies. EDITGENE recommends this model for researchers investigating reverse cholesterol transport, HDL biogenesis, and cardiovascular disease biology.

Yes. ABCA1 rescue experiments are well-established for cholesterol efflux research: • Construct design: use a codon-modified ABCA1 sequence with a small intracellular tag (FLAG, HA). ABCA1 is a full ABC transporter with two transmembrane domains, two large extracellular loops, and two nucleotide-binding domains — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization before cholesterol efflux assays. • Transport-deficient rescue: Walker A motif mutations abolish ATP-dependent lipid efflux. • Tangier disease mutation rescue: patient-derived ABCA1 mutations enable disease modeling. • Functional readout: rescue should restore apoA-I-mediated cholesterol efflux. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.